Now that boceprevir is out with WAC of $1100 per week. For treatment naive patients it will be around $33,000 p.a and $48,000 for full course of 44 weeks.
Can we expect telaprevir to be in the same price range? I don't want to lose my job!
Other things you don't get with Boceprevir:
Rash
Itching
Hemorrhoids
diarrhea
anal itching
other anorectal discomfort
oh and let's not forget, 4x the price.
Oh wait, but that's only for 12 weeks. Easy for you to say that to someone else huh? LMAO
It is obvious that you do not have virology experience. You cannot compare these numbers. Look at the control arms. You look at success by comparing how much you improved over your standard of care. Even then, sometimes low patient numbers in a given arm will throw this off. Doctors will make their decision by efficacy, safety, and support programs offered by the companies. This is triple therapy and patients will need help to reach these great svr numbers.
It is obvious that you do not have virology experience. You cannot compare these numbers. Look at the control arms. You look at success by comparing how much you improved over your standard of care. Even then, sometimes low patient numbers in a given arm will throw this off. Doctors will make their decision by efficacy, safety, and support programs offered by the companies. This is triple therapy and patients will need help to reach these great svr numbers.
Wow the attitude of the vertex reps is amazing. One of the post simply pointed out the basics of what you look for in a study which is improvement over control arm. You cannot compare these studies due to the patients enrolled being different. If you are not going to address compliance and patient needs good luck. Triple therapy will not be a cake walk for patients or for the doctors that treat these patients. The way these post talk truly show that these rep's care only about themselves and their sales. Physicians will begin to read this attitude and it will effect these rep's.
WOW! Had a physician tell me today that she finds NO REASON to use INCIVEK bc of the challenges to manage the multiple DDI's and it does NOT reflect a viable approach when looking at the cost to the healthcare system. SHE SAID: "VERTEX ought to be ashamed of themselves for pricing a 12wk. course of therapy at $48K. ARE THEY THAT DESPERATE FOR CAPITAL AT THE EXPENSE OF THIER REPUTATION?"
As I said, the ONLY hope for Merck is built upon economic strategy. One doctor means nothing. There is a reason that ALL analysts believe that the Vertex drug will capture AT LEAST 75% of the market, and that reason is that the Vertex drug is clearly superior. If you are a Merck rep, just put your market share where your mouth is. Allowing for parity coverage, if your drug is superior, in a few months we should all expect to see your drug at 51%+. There is no need to argue here; the market will determine who is correct.
Hey Dope! VTRX have you noticed the stock price recently?
No, but whats that got to do with my comment? The fact is that NO ANALYST expects Merck to get more than 25% of the market, none. Please do us all a favor and include a link to an article that suggests an expectation that Merck will prevail. You simply cant do it. This battle will be won or lost by science. If the SVRs in the studies playout in the clinics, Merck has no shot. I dont work for Vertex, just being objective.
By the way, no need to use immature insults, lets stick to fgacts, science, logic.
Get over yourself you big dope! Forget science, logic, fgacts (try spell check) etc...Merck and Roche will outspend, outman and outsmart Vertex.
This is pharma and cash rules! Get with the program or get out!
It is obvious that you do not have virology experience. You cannot compare these numbers. Look at the control arms. You look at success by comparing how much you improved over your standard of care. Even then, sometimes low patient numbers in a given arm will throw this off. Doctors will make their decision by efficacy, safety, and support programs offered by the companies. This is triple therapy and patients will need help to reach these great svr numbers.
